; (G) communication, both proactive and reactive, of scientific, medical, or technical information or findings, including communication of such information by personnel in scientific, medical, or clinical development departments of manufacturers; and (H) communication, both proactive and reactive, of health care economic and health outcomes information, including communication of such information delivered by or on behalf of the health care economic or health outcomes departments of manufacturers to an individual, group of individuals, or entity responsible for contributing toward, advising, or facilitating decisionmaking related to health care resource or utilization management, including decisions about the selection of drugs, biological products, or devices for a population of patients. (4) Rule of construction Nothing in this subsection shall be construed— (A) to authorize the Secretary to require that a manufacturer or sponsor submit an application, certification, or other such submission, or to seek the Secretary’s review or approval, before, during, or subsequent to engaging in scientific exchange; or (B) to limit the ability of manufacturers or sponsors to engage in communications or activities that properly constitute scientific exchange as that term is described in paragraph (2) but that are not specified in paragraph (3). .